Business
COVID-19 vaccine Phase I/II showed immune response
COVID-19 vaccine Phase I/II showed immune response.
About this update from Astrazeneca Plc
[{"type":"text","content":"\n \n \n RNS Number : 5251T\n AstraZeneca PLC\n 20 July 2020\n \n \n \n 20 July 2020 14:40 BST\n \n \n \n \n \n COVID-19 \n \n \n vaccine \n \n \n AZD1222\n \n \n showed robust\nimmune responses in all participants in Phase I/II trial\n \n \n \n \n \n \n Interim data showed strong antibody and T-cell responses\n \n \n Interim results from the ongoing Phase I/II COV001 trial, led by Oxford University, showed AZD1222 was tolerated and generated robust immune responses against the SARS-CoV-2 virus in all evaluated participants.\n \n COV001 is a blinded, multi-centre, randomised controlled Phase I/II trial with 1,077 healthy adult participants, aged 18-55 years. It assessed a single dose of AZD1222 against a comparator meningococcal conjugate vaccine, MenACWY. Ten participants also received two doses of AZD1222 one month apart.\n \n The results published in The Lancet confirmed a single dose of AZD1222 resulted in a four-fold increase in antibodies to the SARS-CoV-2 virus spike protein in 95% of participants one month after injection. In all participants, a T-cell response was induced, peaking by day 14, and maintained two months after injection.\n \n Neutralising activity against SARS-CoV-2 (as assessed by the MNA80 assay) was seen in 91% of participants one month after vaccination and in 100% of participants who received a second dose. The levels of neutralising antibodies seen in participants receiving either one or two doses were in a similar range to those seen in convalescent COVID-19 patients. Strong correlations were observed across neutralisation assays.\n \n The early safety responses confirmed that transient local and systemic reactions were common in the AZD1222 group and were comparable to previous trials and other adenoviral vector vaccines.1-4 They included temporary injection site pain and tenderness, mild-to-moderate headache, fatigue, chills, feverishness, malaise and muscle ache. No serious adverse events were reported with AZD1222, and reactions were lessened with the use of prophylactic paracetamol, a pain killer, and occurred less frequently after a second dose.\n \n Professor Andrew Pollard, Chief investigator of the Oxford Vaccine Trial at Oxford University and co-author of the trial, said: \"The interim Phase I/II data for our coronavirus vaccine shows th...